US 12,152,064 B2
BTNL3/8 targeting constructs for delivery of payloads
Oliver Nussbaumer, London (GB); Oxana Polyakova, London (GB); Raj Mehta, London (GB); Adrian Hayday, London (GB); Pierre Vantourout, London (GB); Iva Zlatareva, London (GB); Daisy Melandri, London (GB); Robin John Campbell Dart, London (GB); and Adam Laing, London (GB)
Assigned to King's College London and GammaDelta Therapeutics Limited, London (GB)
Appl. No. 16/972,534
Filed by KING'S COLLEGE LONDON, London (GB); and GAMMADELTA THERAPEUTICS LIMITED, London (GB)
PCT Filed Jun. 5, 2019, PCT No. PCT/EP2019/064739
§ 371(c)(1), (2) Date Dec. 4, 2020,
PCT Pub. No. WO2019/234136, PCT Pub. Date Dec. 12, 2019.
Claims priority of provisional application 62/680,932, filed on Jun. 5, 2018.
Prior Publication US 2021/0246187 A1, Aug. 12, 2021
Int. Cl. C07K 14/725 (2006.01); A23L 33/15 (2016.01); A23L 33/18 (2016.01); A61K 31/4164 (2006.01); A61K 31/43 (2006.01); A61K 31/437 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/52 (2006.01); A61K 31/573 (2006.01); A61K 31/606 (2006.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC C07K 14/7051 (2013.01) [A23L 33/15 (2016.08); A23L 33/18 (2016.08); A61K 31/4164 (2013.01); A61K 31/43 (2013.01); A61K 31/437 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/52 (2013.01); A61K 31/573 (2013.01); A61K 31/606 (2013.01); A61K 38/1841 (2013.01); A61K 38/2066 (2013.01); A61K 45/06 (2013.01); C07K 16/241 (2013.01); C07K 16/244 (2013.01); C07K 16/2803 (2013.01); C07K 16/2839 (2013.01); C07K 2317/565 (2013.01)] 15 Claims
 
1. A protein construct, comprising:
a BTNL3/8 targeting moiety;
a payload; and
an optional linker linking the BTNL3/8 targeting moiety to the payload;
wherein the BTNL3/8 targeting moiety comprises a T cell receptor (TCR) Vγ domain;
wherein the TCR Vγ domain comprises a J region and complementarity-determining regions CDR1, CDR2, CDR3, and CDR4;
wherein the TCR Vγ domain CDR4 is located between the CDR2 and the CDR3 regions of the TCR Vγ domain;
wherein the amino acid at sequence position number 87 of the TCR Vγ domain is aspartic acid or histidine, and the amino acid at sequence position number 90 of the TCR Vγ domain is glycine or glutamic acid;
wherein the remaining residues of the TCR Vγ domain CDR4 are, at each position, independently selected from the corresponding residues of a human or murine Vγ domain; and
wherein the payload is a protein payload fused in-frame to the BTNL3/8 targeting moiety or is a small molecule.